Elizabeth R. Plimack MD MS @ERPlimackMD Of The Fox Chase Cancer Center Discusses Metastatic RCC Metastasectomy Study: Procedure Does Not Prolong Survival, Trend Towards Worse OS, No Benefit To Relapse Free Survival At 3 Years.
Advertisement
Metastatic RCC Metastasectomy Study: Procedure Does Not Prolong Survival, Trend Towards Worse OS, No Benefit To Relapse Free Survival At 3 Years
By Editor